Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 12:56 AM
Ignite Modification Date: 2025-12-25 @ 11:11 PM
NCT ID: NCT00511667
Description: None
Frequency Threshold: 5
Time Frame: Approximately 30 days after last dose of study drug (14 days for participants receiving MK-0941 40 mg before each meal)
Study: NCT00511667
Study Brief: A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
MK-0941 All participants receiving any dose of MK-0941 None None 0 52 27 52 View
Placebo All participants receiving any dose of placebo None None 0 18 11 18 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Musculoskeletal pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (13.0) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (13.0) View
Peripheral coldness SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (13.0) View
Anaemia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (13.0) View
Eye pruritus SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (13.0) View
Lacrimation increased SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (13.0) View
Aphthous stomatitis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (13.0) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (13.0) View
Hypoglycaemia SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (13.0) View
Joint swelling SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (13.0) View
Pain in extremity SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (13.0) View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (13.0) View
Dysuria SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA (13.0) View
Pruritus SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (13.0) View
Eye pain SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (13.0) View
Abdominal pain SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (13.0) View
Vulvovaginal mycotic infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (13.0) View